TPST
USDTempest Therapeutics Inc. Common Stock
即時價格
價格圖表
關鍵指標
市場指標
開盤
$7.932
最高
$7.975
最低
$7.658
交易量
0.00M
公司基本面
市值
28.3M
行業
生物科技
國家
United States
交易統計
平均交易量
0.06M
交易所
NCM
貨幣
USD
52週範圍
相關新聞
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success
Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer program.
Scotiabank Downgrades Tempest Therapeutics to Sector Perform, Lowers Price Target to $9
Scotiabank analyst George Farmer downgrades Tempest Therapeutics from Sector Outperform to Sector Perform and lowers the price target from $91 to $9.
HC Wainwright & Co. Downgrades Tempest Therapeutics to Neutral, Maintains Price Target to $16
HC Wainwright & Co. analyst Joseph Pantginis downgrades Tempest Therapeutics from Buy to Neutral and maintains the price target from $16 to $16.
Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carcinoma (HCC); global investigator support in placeAwarded both Orphan Drug & Fast Track
相關股票
LENZ
LENZ Therapeutics Inc.
CTLT
Catalent
NIE
Virtus Equity & Convertible Income Fund Common Shares of Beneficial Interest
FBIOP
Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
FEXD
Fintech Ecosystem Development Corp.
保持更新
設定價格提醒，獲取AI分析更新和即時市場新聞。